Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2003
11/20/2003US20030216307 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
11/20/2003US20030216306 Therapeutic uses of glandular kallikrein
11/20/2003US20030216305 Identification and characterization of a polypeptide having homology to the sarcoma-amplified protein SAS
11/20/2003US20030216304 Novel proteins and nucleic acids encoding same
11/20/2003US20030216303 Emulsion preconcentrates containing cyclosporin or a macrolide
11/20/2003US20030216302 Desmopressin or its salts in a carrier, a buffer, a para-hydroxybenzoate preservative, and a cosolvent; stable at room temperatures; suitable for nasal administration
11/20/2003US20030216301 Such as (6R,20aS)-16-chloro-6-cyclohexyl-2,3,6,7,9,10,18,19-octahydro-1H- pyrrolo-(1,2-j)(1,4,7,10,13)-benzoxatetraazacyclohexadecine -5,8,11,20(12H,20aH)-tetrone
11/20/2003US20030216300 Lectins as anti-fibrotic agents
11/20/2003US20030216299 Stimulating the proliferation or survival of a hematopoietic cell
11/20/2003US20030216298 Peptide conjugated anti-cancer prodrugs
11/20/2003US20030216297 Pharmaceutical composition
11/20/2003US20030216295 E-selectin-dependent cell adhesion antagonists
11/20/2003US20030216294 Synergistic effect of a sulfonylurea and/or non-sulfonylurea Kchannel blocker, and a phosphodiesterase 3 type inhibitor
11/20/2003US20030216293 Gonadotropin-releasing hormone analogue such as buserelin, leuprorelin or goserelin; optionally with a substance which blocks the androgenic receptors in the brain.
11/20/2003US20030216292 Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
11/20/2003US20030216291 Treatment of shock using adrenomedullin and adrenomedullin binding protein-1
11/20/2003US20030216290 Methods and compositions of treating and/or preventing diabetic retinopathy with pericyte apoptosis inhibitors
11/20/2003US20030216288 Methods and compositions for treating aids and HIV-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules
11/20/2003US20030216287 N-(2-chlorophenyl) hydroxy- or alkoxyalkanamides, e.g.,N-(5-Chloro-2-hydroxyphenyl)-2-(2-hydroxyphenoxy)acetamid e); can deliver a broad range of active agents by various routes.
11/20/2003US20030216286 Methods and compositions for inhibiting angiogenesis
11/20/2003US20030215947 Methods for enhancing targeted gene alteration using oligonucleotides
11/20/2003US20030215944 Comprise nucleotide sequences which target and suppress express for nucleic acids coding receptor protein for treating cancer and psoriasis; gene expression inhibition
11/20/2003US20030215943 Antisense modulation of apolipoprotein B expression
11/20/2003US20030215921 Vascular endothelial growth factor-2
11/20/2003US20030215919 Phosphodiesterase 8A
11/20/2003US20030215918 Comprises nucleotide sequences coding tyrosine kinase receptor binding protein (EFL-1) for treating and diagnosing cell proliferative disorders
11/20/2003US20030215916 Comprises nucleotide sequences coding membrane protein for diagnosisng and treating tumor, nervous sytem, reproductive, pain and sexual disorders
11/20/2003US20030215905 Secreted and transmembrane polypeptides and nucleic acids encoding the same
11/20/2003US20030215904 Comprises membrane protein for treatment and diagnosis of cell proliferative disorders; antitumor/anticarcinogenic agents
11/20/2003US20030215898 Methods for using 22045, a human cyclic nucleotide phosphodiesterase
11/20/2003US20030215885 Using presence of antibody complex to diagnose inflammatory diseases; antiiflammatory agents; immunoassay
11/20/2003US20030215884 Preparing membrane protein for treatment and prevention of parkinson's, alzheimer's and neurodegenerative diseases
11/20/2003US20030215852 Novel pancortin-Pablo protein interactions and methods of use thereof
11/20/2003US20030215850 Comprises nucleotide sequences coding thrombin-activatable fibrinolysis inhibitor (TAFI) for treatment, prevention and diagnosis of blood disorder
11/20/2003US20030215847 Comprises nucleotide sequences coding polypeptides for use in diagnosis, prevention and treatment of bone disorders; tissue engineering
11/20/2003US20030215840 Identifying compounds capable of treating atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, heart failure, thrombosis and endothelial cell disorders
11/20/2003US20030215838 Cytokine receptor zcytor17 multimers
11/20/2003US20030215836 Bone morphogenic protein polynucleotides, polypeptides, and antibodies
11/20/2003US20030215831 Renal regulatory elements and methods of use thereof
11/20/2003US20030215829 Nuclear hormone receptors
11/20/2003US20030215824 Identifying modulators of apoptosis such as XIAP associated factor 1 (XAF-1); for treating and diagnosing cell proliferative disorders; drug screening; antiproliferative agents
11/20/2003US20030215823 Uses of galanin GALR2 receptors
11/20/2003US20030215822 Comprises nucleotide sequences coding polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune/inflammatory, cardiovascular, neurological and developmental disorder
11/20/2003US20030215820 Regulators of type-1tumor necrosis factor receptor and other cytokine receptor shedding
11/20/2003US20030215803 Isolated polynucleotide which hybridizes to given sequence; use in diagnosing cancer and for inhibiting tumor growth
11/20/2003US20030215792 Nucleic acid molecule comprising a nucleic acid sequence coding for a chemokine, a neuropeptide precursor, or at least on neuropeptide
11/20/2003US20030215542 Reduction of cystine containing polypeptides such as gliadins, glutenins, albumin or globulins, using thioredoxin or transferase enzymes; deactivation of neurotoxins
11/20/2003US20030215514 Dispersible macromolecule compositions and methods for their preparation and use
11/20/2003US20030215512 Stable glassy state powder formulations
11/20/2003US20030215510 A delayed delivery drug dose to a fluid environment consists of a dose of drug, a second formulation with imbibes fluid and expands, a wall that confines both and permeable to the passage of fluid, a subcoat of hydroxyalkyl cellulose
11/20/2003US20030215506 Methods and compositions for enhancement of creatine transport
11/20/2003US20030215496 Solid carrier includes a hydrophililc surfactant and a drug
11/20/2003US20030215494 Administering a dose of a lipid-drug enhancer liposomal complex; and in sequence, administering a dose of lipid-anicancer drug liposomal complex via aerosolization from a nebulizer, to inhibit growth of lung metastases
11/20/2003US20030215489 Chemosensitizing with liposomes containing oligonucleotides
11/20/2003US20030215469 Multicomponent meningococcal vaccine
11/20/2003US20030215461 Immunogenic composition comprising adenyl cyclase-hemolysin protein, or portion thereof, strain of Bordetella chosen from B.pertussis, B.parapertussis or B.bronchiseptica, bacterial extract containing expression product of bordetella vrg genes
11/20/2003US20030215460 Methods and compositions for inducing an immune response
11/20/2003US20030215458 Comprise wilms' tumor suppressor gene(wt1) polynucleotide, polypeptide, antigen-presenting cell presenting WT1 polypeptide, antibody that specifically binds to or T cell that specifically reacts with WT1 polypeptide; immunotherapy
11/20/2003US20030215456 Administering either sequentially in any order or simultaneously amounts of at least two therapeutic agents selected from a compound which is a PSA conjugate and a tachykinin receptor antagonist
11/20/2003US20030215451 In treatment (including prevention) or identification of a human subject at risk of tissue damage, preferably liver or heart tissue damage
11/20/2003US20030215449 Method of treating or delaying onset of angiogenic-associated disorder comprising administering to subject an antibody to the polypeptide of SEC1 in an amount sufficient to treat or prevent said angiogenic associated disorder
11/20/2003US20030215448 Compositions and methods for treating hyperimmune response in the eye
11/20/2003US20030215446 CATT-tetranucleotide repeat polymorphism at position-817 of the human Mif gene that functionally affects the activity of the Macrophage Inhibitory Factor (MIF) promoter in gene reporter assays
11/20/2003US20030215445 Concerns an 88 kDa glycoprotein growth factor ("GP88" or "PCDGF") and compositions and methods which affect the expression and biological activity of GP88; useful for diagnosis and treatment of diseases
11/20/2003US20030215444 And stimulate erythropoiesis; teatment of anemia
11/20/2003US20030215443 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
11/20/2003US20030215442 Methods and compositions for the treatment or prevention of immune disorders using combination therapy
11/20/2003US20030215440 Antithrombotic thrombin variants
11/20/2003US20030215439 Administering to a subject at risk of developing the disease an amount of a PAF-AH product effective to prevent diabetes mellitus
11/20/2003US20030215438 Enzyme treatment of foodstuffs for celiac sprue
11/20/2003US20030215436 Anitmicrobial polymer conjugates
11/20/2003US20030215434 Treatment of multiple sclerosis (MS)
11/20/2003US20030215433 Disinfecting or sterilizing a surface of prosthetic device or catheter, preventing or breaking a bacterial biofilm growth, administering bactericide enzyme lysostaphin
11/20/2003US20030215432 Increasing blood-brain barrier permeability for drug deliverying by administering a hyaluronidase and active materials
11/20/2003US20030215431 Management of mucosal viscosity by TFF monomer peptides
11/20/2003US20030215429 Lyophilised or sonicated Lactobacillus bacteria, grampositivie bacteria, gramnegative bacteria; antitumor agents, therapeutic treatment of autoimmune diseases, gastrointestinal disorders, nervodegenerative diseases
11/20/2003US20030215428 Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis
11/20/2003US20030215424 Method of modulating angiogenesis
11/20/2003US20030215423 Drug delivery a genetic engineered vector, encoding protein hormone in vivo; a helper dependent adenoviral vector
11/20/2003US20030215420 Novel therapeutic treatment of chronic obstructive pulmonary disease
11/20/2003US20030215402 Porphyromonas gingivalis recombinant proteins and truncations
11/20/2003US20030215398 Method for administering brain-derived neurotrophic factor to the brain
11/20/2003US20030215395 Cationic amine polymer, cationic peptide or cationic carbohydrate and at least one degradable linker molecule connecting said cationic molecules in a branched arrangement
11/20/2003US20030215388 Can be administered in conjunction with radiation or chemotherapeutic agents.
11/20/2003US20030213920 Methods for sterilizing preparations containing albumin
11/20/2003US20030213047 Necktie wearing device
11/20/2003CA2823041A1 Fgf variants and methods for use thereof
11/20/2003CA2524862A1 Peptides and methods for the control of obesity
11/20/2003CA2492394A1 Induction of antigen specific immunologic tolerance
11/20/2003CA2492044A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
11/20/2003CA2488968A1 Peptides for regulation of urokinase (upa) and tissue type (tpa) plasminogen activator and method of optimizing therapeutic efficacy
11/20/2003CA2485914A1 Artificial extracellular matrix and process for producing the same
11/20/2003CA2485439A1 Anth1 chimeric antagonist
11/20/2003CA2485365A1 Ctp-extended erythropoietin
11/20/2003CA2485363A1 Ferritin fusion proteins for use in vaccines and other applications
11/20/2003CA2485268A1 Resorbable pharmaceutical formulation for the continuous release of thrombin
11/20/2003CA2485256A1 Pathogen vaccines and methods for using the same
11/20/2003CA2485223A1 Active complex of alpha-lactalbumin (hamlet) and cofactor
11/20/2003CA2485138A1 Androgen-regulated pmepa1 gene and methods of using the same to inhibit cancer cell growth
11/20/2003CA2484845A1 Prostate cancer-related compositions, methods, and kits based on dna macroarray proteomics platforms
1 ... 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 ... 3163